Primary microcephaly (PM) is a developmental disorder of early neuroprogenitors that results in reduction of the brain mass, particularly the cortex. To gain fresh insight into the pathogenesis of PM, we describe a consanguineous family with a novel genetic variant responsible for the disease. We performed autozygosity mapping followed by exome sequencing to detect the causal genetic variant. Several functional assays in cells expressing the wild-type or mutant gene were performed to understand the pathogenesis of the identified mutation. We identify a novel mutation in PHC1, a human orthologue of the Drosophila polyhomeotic member of polycomb group (PcG), which significantly decreases PHC1 protein expression, increases Geminin protein level and markedly abolishes the capacity to ubiquitinate histone H2A in patient cells. PHC1 depletion in control cells similarly enhances Geminin expression and decreases histone H2A ubiquitination. The ubiquitination defect and accumulation of Geminin with consequent defect in cell cycle are rescued by over-expression of PHC1 in patient cells. Although patients with the PHC1 mutation exhibit PM with no overt progression of the disease, patient cells also show aberrant DNA damage repair, which is rescued by PHC1 overexpression. These findings reveal several cellular defects in cells carrying the PHC1 mutation and highlight the role of chromatin remodeling in the pathogenesis of PM.
INTRODUCTION
Primary microcephaly (PM) is a phenotype characterized by significant reduction of brain size, particularly the cortex, in the absence of gross-structural defects, and variable degree of intellectual disability (1) . When present in isolation, i.e. non-syndromic, PM is usually inherited as an autosomalrecessive trait with an expansive list of genes identified to date (2) . These genes include MCPH1 (microcephalin), WDR62, CDK5RAP2, CEP152, CEP135, ASPM, CENPJ and STIL, and encode proteins that are almost universally involved in the biology of the centrioles, cellular organelles that play critical roles in cell division and cell cycle checkpoints (1,3 -5) . The conventional view of PM pathogenesis is that abnormal mitosis dynamics in early neuroprogenitors lead to a reduction in the final number of cells that populate the cortex. Specifically, these stem cell-like progenitors that possess the capacity of symmetric and asymmetric cell division lose important regulatory mitotic cues that are required to proliferate and maintain an adequate pool of differentiated cortical neuronal cells (6, 7) . This model is strongly supported by empirical evidence and provides a framework for viewing PM in the context of a generalized biological defect. Indeed, in syndromes that are characterized by severe growth retardation and microcephaly (commonly known as primordial dwarfism with microcephaly), the role of centriolar biology is being increasingly recognized (8) . Conversely, the recent finding that mutation in CENPJ, an established disease gene in PM, can also cause primordial dwarfism with microcephaly further supports the notion that PM can be caused by mutations in genes that are involved in syndromic forms of PM (9) .
Another cause of microcephaly increasingly considered clinically is an underlying defect in DNA damage repair (10 -13) . Fanconi anemia, Nijmegen breakage syndrome, Nijmegen breakage syndrome-like and Bloom syndrome are examples of disorders in which PM ranges from being occasional to a more important clinical feature (13) . BRIT1/ MCPH1, a major gene responsible for PM, is believed to cause PM through its role in mitotic spindle alignment and division plane of neuroprogenitors, and also has an established role in DNA damage response (3, 6) . These observations together with the overlap in the pathogenesis of syndromic and nonsyndromic PM suggest that, in addition to the wellestablished aberrations in cell cycle and abnormal spindle formation seen in cells from patients with PM, DNA damage repair may be an additional abnormal feature. However, whether all cellular defects observed in patient cells are an actual cause of isolated nonsyndromic PM remain unclear.
Polycomb group (PcG) is a term used to describe genes, mutations of which result in abnormal body segmentation in Drosophila similar to that observed in the Polycomb (Pc) mutants, hence their name. PcG proteins associate to form distinct classes of multimeric polycomb repressive complexes (PRCs), such as PRC1 and PRC2. These proteins function as transcriptional repressors that silence specific genes via chromatin remodeling (14) . Specifically, the enzymatic subunits of PRC2 EZH1 and EZH2 are responsible for the di-and trimethylation of Lys27 of histone H3. On the other hand, two subunits of PRC1 Bmi1 and Ring1 act as chromatin remodelers through mono-ubiquitination of histone H2A (15, 16) . PHC1, another component of PRC1, plays a central role in gene regulation but its precise role in the E3 ubiquitin ligase complexmediating H2A ubiquitination remains unknown.
Here, we describe a family with nonsyndromic PM in whom we identify a novel genetic lesion linked to abnormal chromatin remodeling. We discover a novel mutation in PHC1 that markedly abrogates the capacity of patient cells to ubiquitinate H2A, with concomitant increased Geminin expression and several cellular defects, which link for the first time a PcG gene to PM. Mutation in a gene encoding an important chromatin remodeling protein provides fresh insights into the pathogenesis of PM and reveals a new regulatory process controlling brain size.
RESULTS

Identification of a family that defines a novel PM locus
The family was a consanguineous Saudi family consisting of healthy parents, two children (brother and sister) with PM and four healthy siblings. The head circumference of the 13-year-old sister was 25.8SD below the mean, her height was 3.6SD below the mean and the corresponding measurements for her 6-year-old brother were 4.3SD and 2.3SD below the mean, respectively. They both had normal brain MRI results except for a small brain size (Fig. 1A) and functioned in the low-normal range for their chronological age at school. Formal IQ testing revealed a score of 80 in the sister. Their past medical history and physical examination were unremarkable otherwise.
Linkage analysis highlighted two linkage regions neither of which overlaps with known PM genes (Fig. 1B) . The first region on 5q14.1-14.3 (10 MB) only spanned 58 genes, some of which were excluded by direct sequencing (LOC644936, SPZ1, SSBP2). The other region on 12p13.33-12.3 (15 MB) was much more gene-dense spanning 293 genes, including RAD52, RAD51AP1, CDCA3, RAB6IP2, ENO2, PHB2, COPS7A, NDUFA9, LTBR, VAMP1, PTMS, FGF23, EMG1, C12ORF36 and CLECL1. These genes were considered good candidates but later excluded by direct sequencing. The two linkage regions in the family were consistent with homozygosity mapping (Supplementary Material, Fig. S1A ).
Exome sequencing identifies a novel genetic lesion in PM
Given the number of genes in the loci highlighted by autozygosity mapping and our failure to identify mutations in apparently likely candidate genes by direct sequencing, we performed exome sequencing on one affected member. We considered only variants that are homozygous, coding/splicing (excluding synonymous changes), not present in dbSNP, EVS or 1000 Genomes, located within the linkage interval(s), not found in 199 Saudi exomes, and segregated with the phenotype within the family. This approach allowed us to identify one single variant NM_004426.2:c.2974C.T, p.(Leu992Phe) in PHC1 in the 12p13.33-13.1 locus whereas no candidate variants were identified in the other locus (GRCh37/hg19:chr12: 9,092,014) (Fig. 1C) . In addition to being the only novel coding or splicing variant within the candidate runs of homozygosity, the mutation met the following candidacy criteria: conservation across species (Supplementary Material, Fig. S2 ), high pathogenicity score, absence in ethnically matched control chromosomes (554 Saudi individuals were screened for PHC1 mutation) by direct sequencing and absence in the Exome Variant Server.
PHC1 mutation promotes rapid PHC1 degradation
To gain insights into the effect of PHC1 missense mutation, we measured PHC1 protein expression in EBV-transformed lymphoblast cell lines established from three normal individuals and from two patients diagnosed with PM. The relative abundance of PHC1 mRNA was similar in control and patient cells ( Fig. 2A) . In contrast, we observed a marked reduction ( 72%) in PHC1 protein level in patient cells compared with control cells (Fig. 2B) . The significant decrease in PHC1 expression in patient cells was confirmed by performing immunoblotting with a second PHC1 antibody from another commercial source (Supplementary Material, Fig. S3A ) and by indirect immunofluorescence (Supplementary Material, Fig. S3B ). The observation that patient cells express significantly less PHC1 protein than control cells suggested that the reduction of PHC1 may be due to enhanced protein degradation. To test this hypothesis, control and patient cells were treated with cycloheximide to inhibit de novo protein synthesis and the rate of PHC1 protein degradation was measured over time. In patient cells, PHC1 protein half-life was about half that of control cells, where 50% of PHC1 was degraded after 6 h in patient cells whereas the same amount of PHC1 was degraded after 12 h in control cells (Fig. 2C) . Next we investigated whether the proteasome pathway is responsible for PHC1 protein breakdown. For this, control and patient cells were treated with the specific proteasome inhibitor MG-132 for 12 and 24 h, and the PHC1 protein level was analyzed by immunoblotting. Treatment of control and patient cells with MG-132 resulted in stabilization of PHC1 protein (Fig. 2D) , as well as co-treatment of the cells with cycloheximide and MG-132 (Supplementary Material, Fig. S4 ). Therefore, PHC1 mutation enhances the proteasome-mediated degradation of PHC1. PHC1 mutation leads to Geminin accumulation and impairs H2A ubiquitination PHC1 is part of the PRC1, which maintains several genes in a repressive state. This complex includes PHC2 and BMI1 that function as E3 ligase to promote H2A ubiquitination (Ub H2A) (17) . Selected members of the PcG complex are also reported to act as E3 ubiquitin ligase for Geminin (18) . Based on these observations, we examined Geminin protein expression and Ub H2A in control and patient cells. We observed increased Geminin expression in patient cells (Fig. 2E) . Next, we asked whether PHC1 normally interacts with H2A and is implicated in H2A ubiquitination. Endogenous PHC1 was immunoprecipitated from control and patient cells, and its interaction with Ub-H2A was assessed by immunoblotting using a specific anti-Ub-H2A antibody. We detected the association between H2A and PHC1 in control cells. As expected, interaction between H2A and PHC1 was severely reduced in patient cells (Fig. 3A , Supplementary Material, Fig. S4B ). Thus, PHC1 and H2A normally form a (B) Reduced PHC1 protein level in patient lymphoblasts compared with normal controls examined by western blot followed by quantification of normalized PHC1 levels from three biological repeats. 30 mg of whole-cell extract from control lymphocytes of three normal individuals and from Patient 1 and 2 lymphocytes was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 4 -12% NuPAGE gel, and subjected to immunoblotting with PHC1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies. (C) Control and patient cells were incubated with cycloheximide (50 mg/ml) to inhibit general protein synthesis and total cell lysates were analyzed by SDS-PAGE. After transfer of the proteins, PHC1 protein expression was analyzed by immunoblotting using a specific PHC1 antibody. GAPDH was analyzed in parallel as a loading control (n ¼ 3). The half-life based on these experiments is shown in the adjacent graph. (D) Recovery of PHC1 level after treatment with 40 mM of MG-132 proteosome inhibitor. Control 1 and 2 and Patient 1 and 2 cells were treated with MG-132 proteasome inhibitor for the indicated times and were analyzed by immunoblotting using anti-PHC1 antibody. (E) Increased Geminin protein expression in patient cells carrying PHC1 mutation. Thirty micrograms of total cells lysate from control and patient cells were examined by western blot using Geminin and GAPDH-specific antibodies.
protein complex, which is impaired in patient cells due to quantitative defect in PHC1. Next, we asked whether PHC1 mutation affects Ub-H2A. For this, we measured Ub-H2A in control and patient cells by western blot using a specific anti-Ub-H2A antibody recognizing ubiquitinated-Lys119. The reduced level of Ub-H2A was detected in patient cells compared with control cells, whereas the total H2A level was identical in control and patients cells (Fig. 3B ). This result suggests that the reduction of PHC1 in mutant cells alters Geminin expression and impairs H2A ubiquitination.
The results described before suggest that PHC1 mutation may regulate cellular levels of Geminin and that reduction of Ub-H2A in patient cells may be causally linked to the PHC1 mutation. To address this, we specifically silenced PHC1 in control lymphoblasts using RNA interference and measured the impact on Geminin expression and Ub-H2A. We used three different siRNA against PHC1, which all resulted in loss of PHC1, whereas control siRNA had no effect. Specific elimination of PHC1 resulted in increased Geminin expression whereas Ub-H2A was severely reduced Figure 3 . PHC1 mutation increases Geminin expression and H2A ubiquitination. (A) Association between PHC1 and H2A. PHC1 was immunoprecipitated from control and patient cells and the immunoprecipitated material was analyzed by SDS-PAGE. After transfer, membranes were probed with anti-PHC1 or Ub-H2A. Immunoglobulin G antibody was used as negative control in the immunoprecipitation reaction. This experiment was repeated three times. Relative quantification is shown. (B) Reduced H2A ubiquitination in PHC1 mutant cells. Western analysis of total cell lysates from control and patient cells was analyzed using a specific anti-Ub-H2A recognizing Lys 119. GAPDH is shown as a loading control. Relative quantification is shown. (C) Accumulation of Geminin and loss of H2A ubiquitination is a direct consequence of PHC1 mutation. PHC1 was silenced in control cell 1 and 2 using 800 pMol of three different siRNA designed against PHC1. Whole cell proteins lysates were prepared and analyzed by immunoblotting to examine levels of PHC1, Ub-H2A, Geminin and GAPDH were used as internal control. The blot is representative of three independent experiments.
( Fig. 3C) . Together, these results show that PHC1 is required for proper Geminin expression. They also indicate that PHC1 which normally forms a complex with H2A, is necessary for H2A ubiquitination, and that the missense mutation we identified in patient cells impairs this novel function.
PHC1 mutation causes defect in DNA repair at baseline and after irradiation Previous studies have shown that PHC1 primarily localizes in the cell nucleus (19) (20) (21) and that proteins of the PcG in general and PRC1 in particular play a role in DNA repair (22) . In addition, MCPH1 deficiency causes PM and is associated with cellular defects in DNA damage repair (23) (24) (25) . H2A ubiquitination is also essential for DNA repair (26) . Based on these observations, we tested the hypothesis that mutation in PHC1 has effects on cellular functions of the patient cells such as impaired DNA damage response secondary to Ub-H2A reduction. To this end, we used Comet assay that detects both single-strand and double-strand breaks by measuring the amount of DNA that leaks from single nucleus after electrophoresis, at baseline and after treatment with ionizing radiation (IR). Low-level DNA damage was observed in both control and patient cells at baseline (Fig. 4A ) although patient cells had significantly higher damaged DNA compared with control cells (P , 0.02) (Fig. 4B ). Four and 8 h post-IR treatment, patient cells showed a progressive increase in 'comet tail' length indicative of DNA damage, whereas control cells had significantly smaller 'tails' (Fig. 4A and C) . Eight hours post-IR, the average 'tail DNA length' of patient cells was 200 mm whereas 'tail length' in control cells was only 50 mm ( Fig. 4C and D) . Patient cells defective in PHC1 also showed a progressive increase in 'comet tail' length indicative of a defective DNA damage repair after treatment with another DNA damaging agent H 2 O 2 (Supplementary Material, Fig. S5 ). These results indicate impaired DNA damage repair in cells carrying the PHC1 mutation.
PHC1 mutation causes abnormal cell cycle activity PM is characterized by abnormalities in cell cycle progression (27, 28) . Since we observed accumulation of Geminin in patient cells and that Geminin has been shown to play a role in cellular proliferation, we assessed the role of the PHC1 mutation on cell cycle. We performed detailed cell cycle analysis before and after IR treatment in control and patient cells. Before IR treatment, the majority of control cells ( 66%) were in the G1 phase whereas 18% were in G2/M phase. Twenty-four hours post-IR treatment at 10 Gy, a smaller fraction of control cells ( 53%) were in G1 and a significant higher number of control cells ( 30%) were arrested in G2 indicating a proper DNA damage response (Fig. 5A) . In contrast, patient cells showed a different cell cycle profile before and after IR treatment. At baseline, fewer patient cells (31%) were in G1 and a higher fraction ( 44%) were already arrested in G2 phase. Twenty-four hours post-IR exposure, the distribution of patient cells in the G2 phase ( 39%) did not increase, indicating that patient cells have a blunted DNA damage response (Fig. 5A) . Interestingly, we observed a DNA content higher than 4N in patient but not control cells treated with IR, indicating polyploidy in these cells (Fig. 5B) . Mitotic index at baseline was also significantly lower in patient cells compared with control cells. After IR, control cells displayed a reduced mitotic index, whereas mitotic index in patient cells remained mostly unchanged (Fig. 5C ). These observations indicate a reduced proliferative capacity of patient cells compared with control cells.
To understand the effect of the PHC1 mutation on global gene expression, we analyzed gene expression profiling in control and patient cells using microarray analysis. Strikingly, most significantly dysregulated genes in patient cells were involved in cellular growth and proliferation, and cell cycle (P , 10 218 and P , 10 217 , respectively). Genes related to cell death, DNA replication, recombination and DNA repair were also significantly altered in patient cells compared with control cells (P , 10 213 and P , 10
27
, respectively), (Supplementary Material, Fig. S6 ). These data indicate defects in cellular proliferation, cell cycle and DNA repair in patient cells and substantiate our data described before.
The DNA damage defect observed in patient cells suggests that it may be due to impaired recruitment of PHC1 to damaged chromatin. To test this possibility, we performed cell fractionation and measured PHC1 and Ub-H2A expression in the chromatin and nuclear fraction of control and patient cells under basal condition and after IR by western analysis. Under normal conditions, PHC1 was found in the chromatin and soluble nuclear fraction in both control and patient cells. As expected, a lower amount of PHC1 was detected in both fractions in patient cells compared with control cells (Fig. 5D ). IR treatment resulted in a substantial increase in PHC1 binding to chromatin in control cells, whereas the same amount of PHC1 remained bound to chromatin in patient cells (Fig. 5D) . Ub-H2A also increased in control cells after IR exposure, whereas Ub-H2A remained the same in patient cells after IR treatment. These results show that a large fraction of PHC1 is recruited to chromatin regions in control cells in response to DNA damage, which correlates with H2A ubiquitination. This response is significantly reduced in patient cells, suggesting that PHC1 mutation qualitatively impairs the DNA repair response following DNA damage. These results suggest a novel role of PHC1 in DNA damage repair through ubiquitination of H2A. They also show that PHC1 mutation impairs proper expression of PHC1 protein, which results in H2A ubiquitination defect and higher sensitivity to DNA damage. Taken together, these results suggest that mutation in PHC1 induces defects in DNA repair and cell cycle progression, elicited by abnormalities in chromatin regulation.
Over-expression of PHC1 in patient cells rescues cellular defects in DNA damage repair and cell cycle
To further explore the role of PHC1 in the functional defects of patient cells, we restored adequate levels of PHC1 in Patient 1 and 2 cells by overexpressing wild-type PHC1, and measured the impact on H2A ubiquitination and Geminin expression. Increasing PHC1 protein level in patient cells resulted in a progressive increase in Ub-H2A with concomitant decrease in Geminin expression (Fig. 6A ). Next, we tested whether elevated levels of PHC1 can rescue the DNA damage sensitivity and cell cycle abnormalities in patient cells. Patient cells transfected with a shuttle vector showed damaged DNA after IR treatment as indicated by the presence of 'tails' measured by Comet assay. On the contrary, Patient 1 and 2 cells expressing high levels of PHC1 showed minimal DNA damage after IR treatment (Fig. 6B) . The average 'tail' length was 50 mm in patient cells overexpressing PHC1 compared with 200 mm in patient cells transfected with shuttle vector control (Fig. 6C) . Overexpression of PHC1 in patient cells also reversed cell cycle abnormalities. Chromatin and nuclear fractions were isolated from patient and control cells before and after IR exposure (5 Gy), and 30 mg of proteins were subjected to immunoblotting using anti-PHC1 and anti-Ub-H2A antibodies. Total H2A and GATA-4 were used as loading controls in the chromatin and nuclear fraction, respectively. Quantification of this data is shown in (E). (Fig. 6D) . Thus, overexpression of PHC1 can rescue aberrant cell cycle progression. Together, these results indicate that adequate levels of PHC1 are sufficient to ubiquitinate H2A and downregulate Geminin. Normal PHC1 expression is also required for proper progression through the cell cycle and for adequate DNA damage response.
DISCUSSION
PcG proteins consist of two major complexes PRC1 and PRC2, and were originally identified in Drosophila where they form large protein complexes in chromatin to repress homeotic HOX genes during development (29, 30) . Polyhomeotic proteins are core components of the PRC1 and act in concert with Trithorax (Thx) to maintain a tightly regulated spatial domain of expression of HOX genes. (31) Three mammalian orthologs of Ph have been identified, namely PHC1, PHC2 and PHC3, whose role in repressing HOX genes is highly conserved (21) . Despite functional redundancy, individual Ph proteins have unique biochemical properties and are expressed differently in various tissues (14, 32) . Our study now shows that chromatin remodeling complexes are implicated in the pathogenesis of PM. PM has been associated with defects in a number of genes that play a role in centriole biology and mitosis plane (1) . In this study, we identify a family with PM carrying a novel mutation in PHC1, which links, for the first time, PM to abnormal chromatin modifications (Fig. 7) .
A prominent effect of the PHC1 mutation is to reduce PHC1 protein abundance secondary to increased degradation by the proteasome. Since PM has been linked to cell cycle abnormalities previously, we performed detailed cell cycle analysis in control and patient cells. Cell cycle profiles revealed that the mutation is pathogenic as a striking cell cycle block was observed in patient cells at baseline that was rescued by PHC1 overexpression. Our microarray analysis revealed that a large number of genes involved in cell cycle regulation are dysregulated in patient cells. Therefore, the PHC1 mutation recapitulates an important cellular feature of cells isolated from PM patients. Cells carrying the PHC1 mutation have also increased Geminin expression, which was recapitulated in RNAi experiments in control cells and in patient cells where PHC1 was ectopically expressed. Since Geminin has an established role in cell cycle control (33, 34) , PM pathogenesis could be due in part to cell cycle abnormalities as a consequence of Geminin accumulation. This possibility is currently under investigation.
Several proteins involved in PM and members of the PRC play critical roles in DNA repair pathway (3, 23, 25) . Based on these observations, we tested the possibility that cells isolated from affected individuals display functional abnormalities linked to DNA repair defects. Our results show reduced H2A ubiquitination, impaired recruitment of PHC1 to chromatin regions in response to DNA damage and reduced repair of DNA lesions in patient cells. Gene expression profiling also revealed that among the top 10 dysregulated networks in patient cells were genes involved in DNA repair. Therefore, one likely functional consequence of the PHC1 mutation is to prevent adequate recruitment of PHC1 to DNA lesions through altered chromatin conformation, which in turn impairs the recruitment of DNA repair proteins for efficient DNA repair. Consistent with these, a syndromic form of microcephaly has recently been described where microcephaly is congenital and the underlying mutation in PNKP adversely affects DNA damage repair (35) . It has been hypothesized that Members of the PRC1 complex function as epigenetic silencers through chromatin modifications such as H2A ubiquitination at Lys 119, and are also critical for proper cell cycle progression and DNA repair. PRC1 members also directly interact with geminin to promote its degradation, which in turn controls cell cycle. (B) Mutation in PHC1 reduces PHC1 protein expression, which abrogates H2A ubiquitination and modifies chromatin conformation. As a consequence, several cellular defects including cell cycle abnormalities and defects of DNA legions repair occur, which contribute to different degree to PM pathogenesis. PHC1 mutation also stabilizes geminin, which may also contribute to cell cycle abnormalities observed in patients with PM.
neurons are especially sensitive to DNA damage and that a defect in DNA damage repair will preferentially affect neurons perhaps through activation of DNA damage checkpoints and apoptosis (11) . This study together with our data show clear cellular defects in DNA damage repair in patient cells, thus supporting a link between impaired DNA damage response and PM. However, whether the abnormal DNA damage response plays a prominent role in the disease remains elusive. Indeed, patients in our study were born with PM that is nonprogressive in nature. One possibility is that PHC1 mutation leads to changes in chromatin remodeling with two separate consequences: primarily alteration in cell cycle progression and in rare conditions where DNA damage occurs, impairment in DNA repair. Therefore, it appears that the connection between the cellular defects observed in mutant cells and microcephaly is more complex than previously thought.
Two other members of the PRC1, Ring1 and Bmi1, have been shown to be involved in H2A ubiquitination (17) . Our results now point toward PHC1 as another member of PRC1 that plays a role in this process. Interestingly, the mutation we report here (Leu992Phe) in PHC1 lies within the SAM domain (Supplementary Material, Fig. S7 ), which has been classified as an E2 ubiquitin-conjugating enzyme-binding domain responsible for target protein binding (36) . Thus, it will be important to evaluate in the future whether the PHC1 mutation disrupts interaction with other components of PcG complex, such as Ring1/Bmi/Mel18 and Scmh1.
Mouse Phc1 was originally described as Rae28 and human PHC1 as RAE28 (37, 38) . Rae28/Phc1-deficient mice display cephalic neural crest defect, abnormal facies, parathyroid and thymic hypoplasia together with skeletal and cardiac abnormalities (38) (39) (40) (41) . It is worth highlighting that the absence of the equivalent manifestations in our human patients with PHC1 mutation may be explained on the basis of the different nature of the two mutations, i.e. hypomorphic PHC1 mutation versus nullimorphic Phc1 mutation. Another explanation for the apparent differences in phenotypes between patients carrying the PHC1 mutation and Phc1-deficient mice could be due to the young age of the patients, thus not showing yet the various characteristics seen in Phc1 2/2 mice. Also, although microcephaly was not specifically reported, the available images suggest that Phc1 2/2 mice did have microcephaly (40) .
Overall, the data we present in this study suggest that PM may be a final common pathway of several cellular perturbations including centriolar/mitotic defects, cell cycle abnormalities and DNA damage response defects due to abnormalities in chromatin remodeling. It remains to be seen whether and how these processes also converge in the molecular pathogenesis of PM.
MATERIALS AND METHODS
Human subjects
All patients were evaluated by board-certified clinical geneticists and pediatric neurologists. An informed written consent was used to recruit the patients and their relatives (KFSHRC IRB Protocol #208006).
DNA extraction
A 5 -10 ml venous blood sample was collected in ethylenediamineteraacetic acid (EDTA) and Na-heparin tubes from each subject, parent and sibling. DNA extraction was carried out using Puregene Blood Core Kit C (Qiagen, Germantown, MD, USA) following manufacturer's instructions and quantified using Nanodrop 2000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA).
Genotyping, linkage analysis and homozygosity mapping DNA samples were processed on the Affymetrix Axiom TM Genome-Wide H Array Plate (Affymetrix, Santa Clara CA, USA) following the manufacturer's instruction. Genotypic data were used for linkage analysis and homozygosity mapping using EasyLinkage (V5.08) (42) and AutoSNPa (43), respectively.
PCR and direct sequencing
Mutation-harboring exons (as per exome sequencing) of PHC1 and INO80 were amplified in a Veriti w 96-Well Fast Thermal Cycler (Applied Biosystems, Foster City, CA, USA) in a total volume of 25 ml, containing 20 ng DNA and the recommended amounts of dNTPs (Epicentre Biotechnologies, Madison, WI, USA), primers (Metabion, Martinsried, Germany) and of Hotstar Taq DNA polymerase (Qiagen, Germantown, MD, USA). For polymerase chain reaction (PCR), an initial denaturation step at 958C for 10 min was followed by 35 cycles of denaturation at 948C for 40 s, annealing for 40 s and extension at 728C for 45 s, followed by a final extension step of 728C for 10 min. Primer sequences are available upon request. The PCR amplicons were sequenced by dye termination sequencing using BigDye Terminator Cycle Sequencing V3.1 Kit and Prism 370XL Genetic Analyzer (Applied Biosystems). DNA sequences were analyzed using the Seqman program of the DNASTAR analysis package (Lasergene, Madison, WI, USA).
Exome sequencing
Exome capture was performed using TruSeq Exome Enrichment kit (Illumina) following the manufacturer's protocol. Samples were prepared as an Illumina sequencing library and, in the second step, the sequencing libraries were enriched for the desired target using the Illumina Exome Enrichment protocol. The captured libraries were sequenced using Illumina HiSeq 2000 Sequencer. The reads are mapped against UCSC hg19 (http://genome.ucsc.edu/) by BWA (http://bio-bwa.sourceforge.net/). The SNPs and Indels are detected by SAMTOOLS (http://samtools.sourceforge.net/).
Transformation of control and patient cells with EBV and culture condition
Lymphoblastoid cell lines from healthy donors and patients with PM were established by Epstein -Barr virus (EBV) transformation of peripheral blood mononuclear cells (PBMC). The PBMC were isolated from whole blood by Ficoll-Hypaque gradient and then transformed using EBV-shedding marmoset cell line supernatants (purchased from The Wellcom Trust Centre for Human Genetics, University of Oxford). The cells were further incubated with cyclosporin (CSA, 1 mg/ml and phytohaemagglutinin (PHA) 5 mg/ml, Sigma, USA). All EBVtransformed cell lines were maintained in RPMI 1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Gibco, USA) at 378C and 5%.
Reagents and antibodies
Cycloheximide and MG-132 were purchased from Sigma. Antibodies were obtained from several vendors as follows: PHC1 (Abnova, USA), H2A (Cell Signaling, USA), Ub-H2A (Millipore, USA), g-H2AX (Millipore, USA), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Santa Cruz, USA) and PHC1 expression vector (Origene, USA).
Protein extraction and immunoblotting
Cells were harvested by centrifugation and resuspended in lysis buffer (20 mM Tris, pH 7.5, 350 mM NaCl, 0.05% b-mercaptoethanol) containing protease inhibitors (0.2 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 2 mM E64, 2.6 mM aprotinin, 1 mM pepstatin). Total cell extract was obtained by subjecting the pellet to five consecutive cycles of freeze/ thawing in liquid nitrogen. Cell lysate was separated by centrifugation at 12 000 rpm at 48C for 20 min. The concentration of protein lysates was measured by Bradford assay using the Bio-Rad Protein Detection Kit (Bio-Rad, USA). Typically, 30-20 mg of the whole-cell extract was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS -PAGE) on 4 -12% NuPAGE w Novex w Bis-Tris Gels (Invitrogen, USA), followed by transfer of proteins onto nitrocellulose membrane. The membrane was then blocked in TBS -Tween (50 mM Tris, 138 mM NaCl, 2.7 mM KCl, 0.05% Tween 20, pH 8.0) containing 5% milk. Subsequently, the membrane was incubated with the indicated primary antibody in TBSTween 20 overnight at 48C at 1:1000 dilution. After washing, secondary reactions were carried out with secondary antibodies (dilution 1:3000) for 1 h. Signals were visualized by chemiluminscence using ImageQuant LAS 4000 mini (GE Healthcare, UK).
Cycloheximide and proteasome inhibitor treatment
Cells were treated with cycloheximide (50 mg/ml) for 6, 12 and 24 h to inhibit de novo protein synthesis. Total cell lysates were prepared at the end of the treatment and 30 mg of cellular proteins were analyzed by SDS -PAGE on 4-12% gradient gel as described before. To examine proteosomal degradation, control and patient cells were treated with dimethylsulfoxide (DMSO) or 40 mM MG-132 proteasome inhibitor for 12 and 24 h. Cell lysates were analyzed by western blotting with the corresponding antibodies as described before.
Immunostaining
Cells were plated on coverslides in six-well dishes at a density of 0.5 × 10 6 cells/well. After fixation in formaldehyde, cells were permeabilized and stained with anti-PHC1 antibody followed by fluorescein isothiocyanate-conjugated anti-rabbit immunoglobulin G (Sigma, dilution 1:100). The cover slides were mounted with Vectashield mounting media containing 4 ′ ,6-diamidino-2-phenylindole (Vector Laboratories). Signals were observed by fluorescence microscopy using a Nikon Eclipse Ti-E microscope.
siRNA gene silencing
Control lymphoblasts isolated from two normal individuals were transfected with three different siRNAs (Invitrogen) against PHC1 using Lipofectamine 2000 (Invitrogen) according to manufacturer's instruction. Scrambled control siRNA was used in parallel. Briefly, 800 pM of siRNA and Lipofecatamine were diluted in Opti-MEM media (Invitrogen) and the mixture was added to the cells and incubated for 24 h. Total cell lysates were analyzed by immunoblotting as described before.
Immunoprecipitation
Total cell protein extracts were incubated with Dynal protain A magnetic beads (Invitrogen) coupled to anti-PHC1 (Abnova, USA) polyclonal antibody or anti-ubiquitinated H2A (lys 119) (Millipore) in a pulldown buffer (50 mM N-2-hydroxyethylpiperazine-N ′ -2-ethanesulfonic acid [pH 7.5], 1 mM EDTA, 150 mM NaCl, 10% glycerol, 0.1% Tween 20, 0.5 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride, 2 mg/ml leupeptin and 2 mg/ml pepstatin A). Cell extracts were incubated with the beads overnight at 48C while mixing on a rotating wheel. Beads not conjugated with antibody were used as negative control. Supernatants were collected, and the beads were then washed with pulldown buffer and left as a 50% slurry. Bead fractions were analyzed on 4 -12% SDS-PAGE, and the presence of PHC1 and ubiquitinated-H2A was detected by immunoblotting using the corresponding antibodies.
Comet assay
The comet assay (alkali method) was modified from that described earlier (44) . Roughened microscope slides were dipped briefly into 1.5% hot (608C) normal melting agarose (NMA) (Denville Scientific, USA) prepared in phosphatebuffered saline (PBS). The slides were dried and coated with 300 ml of 1.0% NMA in PBS and the agarose was allowed to solidify. Subsequently, 1000 lymphoblasts (20 ml) cells from normal control and patient cells subjected to +5 Gy of IR were mixed with 95 ml of 0.75% low melting point agarose (LMA) (Sigma). The mixture was spread on the slide using a cover slip and then allowed to solidify at 48C. After removal of the cover slip, the slides were immersed in freshly prepared cold (48C) lysing solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris; pH 10-10.5; 1% Triton X-100 and 10% DMSO added just before use) for at least 2 h. The alkaline unwinding, electrophoresis and neutralization steps were performed by removing the slides from the lysis solution and placing them in the electrophoresis chamber, which was then filled with freshly made alkaline buffer (300 mM NaOH and 1 mM EDTA, pH 12.6). The cells were exposed to alkali for 30 min to allow for DNA unwinding and the expression of alkali-labile sites. Subsequently, the DNA was electrophoresed for 30 min at 300 mA and 25 V. All of the above steps (preparation of slides, lysis and electrophoresis) were conducted under red light or without direct light in order to prevent additional DNA damage. After electrophoresis, the slides were placed in a horizontal position and washed three times (5 min each) with 0.4 M Tris buffer, pH 7.5, to neutralize the excess alkali. Finally, 70 ml of ethidium bromide (2 mg/ml) was added to each slide, which was then covered with a cover slip, stored in a humidified box at 48C and analyzed using a Nikon Eclipse Ti-E fluorescence microscope under ×40 objective with a calibrated ×10 eyepiece. Images of 50 randomly selected cells were analyzed from each sample. Tail lengths (nuclear region+ tail) were measured at ×40 magnification in which one pixel unit was 0.085 mm. The fluorescence microscope was equipped with a BP546/12-nm excitation filter and a 590-nm barrier filter. Cells were also scored visually into two classes, according to tail size (from undamaged to damaged). The final overall rating for the DNA damage score was represented as a value of the average of comet length in 50 cells and error bars represents standard deviation.
Cell cycle analysis
For cell cycle analysis by flow cytometry, cells were seeded in a six-well plate at density of 5 × 10 5 cells per well in 2 ml media. After 18 h, the cells were exposed to 10 Gy of IR and harvested at 0, 24 and 48 h after IR. The cell cycle distribution was then analyzed using propidium iodide (PI) staining followed by flow cytometry using a FACS Calibur flow cytometer (BD Biosciences). For PI staining cells were harvested, washed with PBS and stained for 1 h in a hypotonic solution containing PI (40 mg/ml), 0.1% sodium citrate and 0.1% triton X-100 as described in (45) .
IR Irradiation and chromatin fractionation
Cells were irradiated with 5 Gy IR by XRAD 320 (Precision X-Ray, Inc., USA). Typically, 10 6 cells were used for each extraction. Cells were harvested by centrifugation and were lysed in ice-cold Buffer A [10 mm piperazine-N-N ′ -bis [2-ethane sulfonic acid] (pH 6.8), 100 mM NaCl, 300 mm sucrose, 3 mM MgCl 2 , 1 mM ethylene glycol tetraacetic acid (EGTA), 0.5% Triton X-100 supplemented with freshly added protease inhibitors]. Supernatants were recovered and constituted the soluble fraction. Pellets were washed once in buffer A, lysed in buffer B (350 mM Tris-Cl, pH 8.1, 10 mM EDTA, 1% SDS, 0.2 mM EGTA, 1 mM DTT, protease inhibitors cocktail), incubated on ice for 10 min, and then sonicated on ice for 30 s. Micrococcal nuclease (MNase I) was then added to the homogenate and the chromatin fraction was collected by centrifugation at 14 000 rpm for 10 min at 48C. Proteins from the supernatant and chromatin fraction were analyzed by SDS -PAGE and immunoblotting with the indicated antibodies. Signals were visualized by chemiluminescence as described before.
Gene expression profiling
Lymphoblasts from the two patients in Family 1 and unrelated normal controls (performed in triplicates) were used for global expression profiling using Affymetrix's GeneChip w Human Genome U133 Plus 2.0 Arrays. Sample handling, cDNA synthesis, cRNA labeling and synthesis, hybridization, washing and scanning of chips and all related quality controls were performed according to manufacturer's instructions. Significantly modulated genes were defined as those with absolute fold change (FC) . 2 and adjusted P-value of ,0.05. We used Benjamini -Hochberg step-up procedure to control the false discovery rate (FDR) at 5%. Functional pathway, gene ontology and network analyses were executed using DAVID Bioinformatics Resources, Expression Analysis Systematic Explorer (EASE) and Ingenuity Pathways Analysis (IPA) 6.3 (Ingenuity Systems, Mountain View, CA). A right-tailed Fisher's exact test was used to calculate the P-value determining the probability that the biological function (or pathway) assigned to that dataset is explained by chance alone. Statistical analyses were performed with the MATLAB software packages (Mathworks, Natick, MA, USA), and PARTEK Genomics Suite (Partek, Inc., St. Louis, MO, USA).
Over-expression of PHC1
PHC1 expression vector was from Origene, USA. Control or patient lymphoblasts were transfected with empty shuttle vector or PHC1 expression vector expressing GFP using lipofectamine 2000. Twenty-four hours after transfection, cells were washed and maintained in growing media for 48 h. Subsequently, cells were processed for western analysis, comet assay or cell cycle analysis as described before.
